Feed RXRX
RX

Recursion Pharmaceuticals

RXRX · NASDAQ

$3.89 +6.58% (+$0.24)
1M +11.46%
Market Cap $2.04B
P/E Ratio -
Div. Yield -
ROE 50.41%
Piotroski F-Score Weak
3/9
Valuation
41 /100
Fair
P/B 2.23x
P/S 37.21x
P/FFO N/A
Growth
100 /100
Growing
Book val. growth 32.53%
Rev. growth 23.46%
FCF growth N/A
Profitability
0 /100
Weak
Op. margin 991.72%
Gross margin 46.66%
FCF margin 645.82%
Quality
1 /100
Poor
ROA 42.79%
ROIC 48.34%
Asset turnover 0.05x
Debt
69 /100
Low
Int. coverage -350.41x
Debt/Equity 0.07x
Current ratio 5.03x
Stability
75 /100
Stable
EPS volatility 15.90%
Beta 1.07x
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RXRX
Online

O podjetju

Recursion Pharmaceuticals is a biotechnology company that utilizes modern technologies such as artificial intelligence and machine learning to discover new therapeutic compounds and potential treatment approaches.

The key element of their approach is the use of image processing and data analysis systems to create comprehensive maps of cellular processes. This aims to identify potential targets for drugs and therapeutic substances in the fields of genetics, cellular biology, and diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Najat Khan

Employees

600

Headquarters

Salt Lake City

Prihajajoči dogodki

04 NOV.

Earnings

Upcoming earnings report

40d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.